SEC
ABCL icon

Seven Eight Capital’s AbCellera Biologics ABCL Stock Holding History

Seven Eight Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-54,345
Closed -$1.09M – 427
2021
Q3 		$1.09M Buy
+54,345
New +$961K 0.1% 285

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DB
DCVC Bio Palo Alto, California $313K AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Seven Eight Capital's ABCL Position: Q4 2021 in Review

Seven Eight Capital sold out of AbCellera Biologics (ABCL) in Q4 2021, closing a stake of 54,345 shares — an estimated $1.09M sold.

Seven Eight Capital first reported a position in ABCL in Q3 2021 and held it in 1 quarter. The position peaked at $1.09M in Q3 2021. 124 funds tracked by Wall St. Rank hold ABCL as of Q4 2021.

  • Seven Eight Capital reported no remaining AbCellera Biologics position as of Q4 2021 after selling out during the quarter.
  • Seven Eight Capital sold 54,345 AbCellera Biologics shares in Q4 2021, an estimated $1.09M.
  • Seven Eight Capital first reported a position in AbCellera Biologics in Q3 2021 and held it in 1 quarter.
  • Seven Eight Capital's AbCellera Biologics position peaked at $1.09M in Q3 2021.
  • 124 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2021.

Based on Seven Eight Capital's 13F filing for Q4 2021, filed 14 Feb 2022.